Clinical Trials Browser

Phase 2 × Acrocephalosyndactylia × erdafitinib × Clear all

NCT02699606 2025-04-27

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Phase 2 Completed

GastrointestinalThoracic

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Cholangiocarcinoma